Navigation Links
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Date:7/23/2009

ficacy assessments for each participant were based on the American College of Rheumatology criteria, which denotes at least a 20% (ACR 20) improvement, at least a 50% (ACR 50) improvement, or at least a 70% (ACR 70) improvement, from the baseline assessment at the end of the 3 month treatment period. The ACR measurement factors included reported physician and patient global assessment of disease activity, patient reported pain score, and any change in CRP in the patient's blood. The primary efficacy endpoint for the clinical trial was the percent of patients assigned to the R788 100 mg bid dose who were ACR 20 responders at the end of 3 months. Secondary efficacy endpoints included other ACR scores and, a comparison of response rates for the R788 100 mg bid dose versus placebo as determined by MRI using the modified RAMRIS scoring system of wrists and hands at baseline and at month 3.

R788 and RA

RA is a progressive, painful and potentially debilitating disease, that affects more than 2 million people in the U.S. It is a chronic inflammatory disease that puts the body's immune system into overdrive where it ultimately causes inflammation in the joints and destroys soft tissues, cartilage and bone. Rigel's R788 is a novel, orally available syk kinase inhibitor designed to interrupt the cellular signaling at the trigger point of inflammation, thereby stopping the progression of the disease. In July 2009, Rigel announced results from its Phase 2b TASKi2 clinical trial showing significant improvement in RA patients treated with R788 who had failed to respond to methotrexate treatment.

Conference Call and Webcast Information

Rigel will host a conference call to discuss the R788 TASKi3 Phase 2b clinical trial of R788 in rheumatoid arthritis, the Company's plans for further development and related matters today, July 23, 2009, at 7:00 pm EDT/ 4:00 pm PDT. A presentation related to the TASKi3
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... DIEGO , Nov. 25, 2014 Halozyme Therapeutics, ... the Piper Jaffray Healthcare Conference in New York ... EDT/10:00 a.m. PDT . Dr. Helen Torley , ... The presentation will be webcast through the "Investors" ... a recording will be made available for 90 days following ...
(Date:11/24/2014)... Nov. 24, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... a corporate overview and update at the Piper Jaffray 26 ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), at ... . A live audio webcast of the ... Arena,s website at www.arenapharm.com . A replay of the ...
(Date:11/24/2014)... -- Marta Rendon, MD, founder of the Rendon Center for Dermatology ... international key opinion leader in dermatology, was one of only ... to attend the international Aesthetic Experts Summit held ... at this gathering of over 600 physicians from 57 countries, ... experts from Asia and ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3
... Alcona Health Center is one of the first organizations ... payment after successfully meeting the requirements for Year One ... Alcona Health received a first-year incentive payment for each ... Medicare and Medicaid Services, resulting in one of the ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), ... that Jeffrey H. Burbank, Chief Executive Officer, will present ... September 20th, at 3:00 p.m. ET.   A webcast ... http://www.nxstage.com/ir.cfm at the time of the presentation. ...
Cached Medicine Technology:SuccessEHS Client Among First in State of Michigan to Receive Medicaid Stimulus Funds 2SuccessEHS Client Among First in State of Michigan to Receive Medicaid Stimulus Funds 3SuccessEHS Client Among First in State of Michigan to Receive Medicaid Stimulus Funds 4
(Date:11/24/2014)... York, NY (PRWEB) November 24, 2014 From ... the progressive world of fitness technology will take center stage ... in Digital Times at the 2015 International CES® ... in the Venetian, Level 2, Bellini 2004). The bond between ... evolves into being less about devices and more about the ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Volpara ... version 1.2 at the 100th Annual Meeting of ... 30-December 5, 2014 (RSNA Booth 1752 – South ... of VolparaAnalytics and the rest of its innovative ... and VolparaDoseRT, which enable personalized measurements of volumetric ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Olaparib functions ... polymerase (PARP) and is one of the first PARP ... to creating some types of melanoma, and are often ... also sometimes gives their malignancies a exclusive weaknesses, as ... to fix their DNA and allow them to proceed ...
(Date:11/24/2014)... Mental health issues affect tens ... up families, ruin careers, and generally destroy lives. ... that suffer,” says Hardy Nutritionals® founder ... our specialized nutritional treatments can reverse these disorders ... Over Matter”, the premiere episode of O2 Media’s ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Gersowitz Libo & ... it has received national Tier recognition in the 2015 Edition ... a tiered ranking signals a unique combination of quality law ... proud to receive this honor and especially grateful to our ... important honor and ranking possible,” said Jeff S. Korek, senior ...
Breaking Medicine News(10 mins):Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2
... ... ... , ... , , , ...
... workshop have been released to address deep-vein thrombosis (DVT) ... estimated to affect nearly 1 million Americans each year. ... representatives from federal health agencies and patient groups, as ... communities appear in the March 9, 2010, ...
... a successful relationship partners shouldn,t go to bed angry. ... that brain activityspecifically in the region called the lateral prefrontal ... in the days following a fight with his or her ... lateral prefrontal cortex are less likely to be upset the ...
... oophorectomy) while performing a hysterectomy is common practice to ... procedure is performed in 55 percent of all US ... year. An article in the March/April issue of t ... ovaries (bilateral oophorectomy) while performing a hysterectomy is common ...
... anxiety, depression and stress lessened, researchers say , TUESDAY, March ... psychological woes in patients with lupus who have high levels ... also helps these patients improve and maintain their quality of ... included 45 patients randomly assigned to a control group or ...
... ... only seven one-hundredths of one percent of the products manufactured by the company. , ... Dinuba, CA (Vocus) March 9, 2010 ... potential salmonella exposure. To date, no salmonella-related illnesses have been reported in conjunction to ...
Cached Medicine News:Health News:South Dakota Students with Asthma Can Breathe Easier After New Law Allows Self-Administered Medications 2Health News:Critical recommendations unveiled: Deep-vein thrombosis and pulmonary embolism 2Health News:Critical recommendations unveiled: Deep-vein thrombosis and pulmonary embolism 3Health News:After a fight with a partner, brain activity predicts emotional resiliency 2Health News:New study questions benefits of elective removal of ovaries during hysterectomy 2
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... offers a complete line of flowmeters, ... CO 2 . They are all ... to best suit your application. With ... to the gas in use, the ...
Medicine Products: